ENGINEERED ANTI-IL-2 ANTIBODIES

Described herein are engineered anti-IL-2 antibodies with modified amino acid sequences. The engineered antibodies would confer modified receptor binding specificity to an IL-2-anti-IL2 antibody complex, inhibiting the binding of IL-2 to CD25. The engineered anti-IL-2 antibodies would facilitate exp...

Full description

Saved in:
Bibliographic Details
Main Authors Sharon FISCHMAN, Timothy WYANT, Yehezkel SASSON, Yanay OFRAN, Guy NIMROD, Noam GROSSMAN, Natalia LEVITIN, Itay LEVIN, Reut BARAK FUCHS, Inbar AMIT, Olga BLUVSHTEIN YERMOLAEV, Marek ŠTRAJBL, Michael ZHENIN
Format Patent
LanguageEnglish
Published 07.12.2023
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Described herein are engineered anti-IL-2 antibodies with modified amino acid sequences. The engineered antibodies would confer modified receptor binding specificity to an IL-2-anti-IL2 antibody complex, inhibiting the binding of IL-2 to CD25. The engineered anti-IL-2 antibodies would facilitate expansion of subsets of effector immune cells and decrease undesirable effects caused by IL-2. Thus, the engineered anti-IL-2 antibodies would be useful in treating disease such as cancer and infection.
Bibliography:Application Number: AU20230266270